crinetics.png
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 08, 2020 09:01 ET | Crinetics Pharmaceuticals, Inc.
Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly Completed successful public offering raising net proceeds of $107.9 million ...
crinetics.png
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
April 15, 2020 00:21 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 09, 2020 16:10 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
February 19, 2020 07:30 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
REZOLUTE.jpg
Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
February 10, 2020 08:30 ET | Rezolute, Inc.
REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical...
REZOLUTE.jpg
Rezolute to Present at BIO CEO & Investor Conference 2020
January 27, 2020 08:30 ET | Rezolute, Inc.
REDWOOD CITY, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical...
crinetics.png
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 02, 2019 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference
November 20, 2018 07:30 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 13, 2018 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology
September 26, 2018 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...